LEHNES PHARMACOTHERAPEUTICS FOR
APNS and PAS COMPLETE MASTER EXAM
BANK 3RD EDITION 2026 2027
ADVANCED PRACTICE PRESCRIPTIVE
AUTHORITY GUIDE
Lehne’s Pharmacotherapeutics for Advanced Practice
Nurses & Physician Assistants (3rd Edition) — Part 1
(Questions 1–25)
1. A 64-year-old male with a history of chronic heart failure
and stage 3 chronic kidney disease is prescribed digoxin
for heart rate control in atrial fibrillation. Knowing the
pharmacokinetics of digoxin in an elderly patient with
compromised renal function, what is the most critical
physiological adjustment the advanced practice provider
must make to prevent toxicity?
• A) Correct Answer: Reduce the maintenance
dose and extend the dosing interval, while
targeting a lower therapeutic serum level (0.5–0.9
ng/mL). Rationale: Digoxin is eliminated primarily by
the kidneys. In an elderly patient with chronic kidney
disease, the half-life is significantly prolonged, and the
volume of distribution is decreased. Advanced practice
guidelines recommend lower therapeutic ranges (0.5–0.9
ng/mL) for heart failure to balance safety and efficacy,
as higher levels increase the risk of lethal arrhythmias
without added benefit.
• B) Increase the maintenance dose to overcome age-related
decreases in gastrointestinal active transport mechanisms.
Rationale: Increasing the dose would rapidly lead to
, digoxin toxicity (nausea, halos, bradycardia, heart
blocks) due to diminished renal clearance.
• C) Administer the medication alongside a high-fiber meal
to accelerate intestinal clearance of active drug
metabolites. Rationale: High-fiber foods and bran
actually bind to digoxin, reducing its absorption and
rendering therapy erratic, rather than acting as a safe
clearance mechanism.
• D) Maintain standard dosing but monitor total serum
digoxin levels every 12 hours for the first week of therapy.
Rationale: Digoxin has a long half-life (around 36–48
hours normally, longer in renal failure) and takes
roughly 5–7 days to reach a steady state; monitoring
every 12 hours initially is clinically useless and costly.
2. A 45-year-old female stabilized on warfarin for a
mechanical mitral valve is diagnosed with a severe
pulmonary infection. A provider initiates a 10-day course
of sulfamethoxazole-trimethoprim (Bactrim). What
molecular mechanism drives the severe drug-drug
interaction expected between these two agents, and what
is the required clinical intervention?
• A) Bactrim induces cytochrome P450 enzymes,
accelerating warfarin metabolism and increasing the risk
of mechanical valve thrombosis. Rationale:
Sulfamethoxazole-trimethoprim is an inhibitor, not an
inducer, of the metabolic pathways that break down
warfarin.
• B) Correct Answer: Bactrim inhibits CYP2C9
enzymes, which slows the clearance of S-warfarin,
sharply increasing the INR and risk of
hemorrhage; the warfarin dose must be
preemptively reduced by 25–50%. Rationale:
, Sulfamethoxazole-trimethoprim is a potent inhibitor of
CYP2C9, the primary isoenzyme responsible for
metabolizing the highly active S-isomer of warfarin.
Inhibiting this enzyme drastically spikes serum warfarin
levels, causing a dangerous jump in the INR. Providers
must preemptively lower the warfarin dose and monitor
the INR closely within 3–5 days.
• C) Bactrim binds directly to serum albumin, displacing
warfarin from binding sites and causing transient
microscopic clots. Rationale: While protein
displacement can occur, the primary and clinically
significant driver of this life-threatening interaction is
active enzyme inhibition.
• D) Bactrim reduces the absorption of vitamin K in the
colon by sterilizing gut flora, which takes 4 to 6 weeks to
manifest. Rationale: While alterations in gut flora can
reduce vitamin K synthesis, enzyme inhibition causes an
immediate and severe spike in INR within days.
3. An advanced practice provider is selecting an empirical
medication regimen for an elderly patient with severe
osteoarthritis who also has a history of a documented
peptic ulcer disease episode. Which pharmacotherapeutic
strategy provides the best balance of pain management
and gastrointestinal safety?
• A) Standard ibuprofen 800 mg three times daily taken
with an over-the-counter antacid. Rationale: High-dose
non-selective NSAIDs like ibuprofen carry a high risk of
GI bleeding in an elderly patient with an ulcer history,
and simple antacids do not provide sufficient mucosal
protection.
• B) Indomethacin 50 mg twice daily combined with a low-
dose H2-receptor antagonist like famotidine. Rationale:
, Indomethacin has a very high rate of GI and CNS
toxicities in older adults and should be avoided; low-dose
H2 blockers do not fully protect against NSAID-induced
ulcers.
• C) Correct Answer: Celecoxib (a selective COX-2
inhibitor) combined with a proton pump inhibitor
(PPI) like omeprazole, or selecting non-NSAID
modalities like topical diclofenac. Rationale:
Celecoxib selectively inhibits COX-2, minimizing the
structural destruction of GI-protective prostaglandins
mediated by COX-1. In a high-risk patient (elderly with a
prior ulcer), pairing a COX-2 inhibitor with a PPI
provides the highest degree of upper GI protection if
systemic NSAID therapy is absolutely necessary. Topical
NSAIDs are even safer due to minimal systemic
absorption.
• D) Naproxen 500 mg twice daily, as it selectively protects
the gastric mucosal barrier while suppressing joint
inflammation lines. Rationale: Naproxen is a non-
selective NSAID that blocks both COX-1 and COX-2; it is
not gastric-protective.
4. A 28-year-old female patient who is at 8 weeks' gestation
requires treatment for severe chronic hypertension. Which
antihypertensive medication is considered safe for use
during pregnancy, and which is strictly contraindicated
due to structural teratogenic risks?
• A) Lisinopril is safe because it preserves renal perfusion;
Methyldopa is contraindicated due to maternal depression
risks. Rationale: ACE inhibitors like lisinopril are
strictly contraindicated in pregnancy due to severe fetal
renal anomalies.
APNS and PAS COMPLETE MASTER EXAM
BANK 3RD EDITION 2026 2027
ADVANCED PRACTICE PRESCRIPTIVE
AUTHORITY GUIDE
Lehne’s Pharmacotherapeutics for Advanced Practice
Nurses & Physician Assistants (3rd Edition) — Part 1
(Questions 1–25)
1. A 64-year-old male with a history of chronic heart failure
and stage 3 chronic kidney disease is prescribed digoxin
for heart rate control in atrial fibrillation. Knowing the
pharmacokinetics of digoxin in an elderly patient with
compromised renal function, what is the most critical
physiological adjustment the advanced practice provider
must make to prevent toxicity?
• A) Correct Answer: Reduce the maintenance
dose and extend the dosing interval, while
targeting a lower therapeutic serum level (0.5–0.9
ng/mL). Rationale: Digoxin is eliminated primarily by
the kidneys. In an elderly patient with chronic kidney
disease, the half-life is significantly prolonged, and the
volume of distribution is decreased. Advanced practice
guidelines recommend lower therapeutic ranges (0.5–0.9
ng/mL) for heart failure to balance safety and efficacy,
as higher levels increase the risk of lethal arrhythmias
without added benefit.
• B) Increase the maintenance dose to overcome age-related
decreases in gastrointestinal active transport mechanisms.
Rationale: Increasing the dose would rapidly lead to
, digoxin toxicity (nausea, halos, bradycardia, heart
blocks) due to diminished renal clearance.
• C) Administer the medication alongside a high-fiber meal
to accelerate intestinal clearance of active drug
metabolites. Rationale: High-fiber foods and bran
actually bind to digoxin, reducing its absorption and
rendering therapy erratic, rather than acting as a safe
clearance mechanism.
• D) Maintain standard dosing but monitor total serum
digoxin levels every 12 hours for the first week of therapy.
Rationale: Digoxin has a long half-life (around 36–48
hours normally, longer in renal failure) and takes
roughly 5–7 days to reach a steady state; monitoring
every 12 hours initially is clinically useless and costly.
2. A 45-year-old female stabilized on warfarin for a
mechanical mitral valve is diagnosed with a severe
pulmonary infection. A provider initiates a 10-day course
of sulfamethoxazole-trimethoprim (Bactrim). What
molecular mechanism drives the severe drug-drug
interaction expected between these two agents, and what
is the required clinical intervention?
• A) Bactrim induces cytochrome P450 enzymes,
accelerating warfarin metabolism and increasing the risk
of mechanical valve thrombosis. Rationale:
Sulfamethoxazole-trimethoprim is an inhibitor, not an
inducer, of the metabolic pathways that break down
warfarin.
• B) Correct Answer: Bactrim inhibits CYP2C9
enzymes, which slows the clearance of S-warfarin,
sharply increasing the INR and risk of
hemorrhage; the warfarin dose must be
preemptively reduced by 25–50%. Rationale:
, Sulfamethoxazole-trimethoprim is a potent inhibitor of
CYP2C9, the primary isoenzyme responsible for
metabolizing the highly active S-isomer of warfarin.
Inhibiting this enzyme drastically spikes serum warfarin
levels, causing a dangerous jump in the INR. Providers
must preemptively lower the warfarin dose and monitor
the INR closely within 3–5 days.
• C) Bactrim binds directly to serum albumin, displacing
warfarin from binding sites and causing transient
microscopic clots. Rationale: While protein
displacement can occur, the primary and clinically
significant driver of this life-threatening interaction is
active enzyme inhibition.
• D) Bactrim reduces the absorption of vitamin K in the
colon by sterilizing gut flora, which takes 4 to 6 weeks to
manifest. Rationale: While alterations in gut flora can
reduce vitamin K synthesis, enzyme inhibition causes an
immediate and severe spike in INR within days.
3. An advanced practice provider is selecting an empirical
medication regimen for an elderly patient with severe
osteoarthritis who also has a history of a documented
peptic ulcer disease episode. Which pharmacotherapeutic
strategy provides the best balance of pain management
and gastrointestinal safety?
• A) Standard ibuprofen 800 mg three times daily taken
with an over-the-counter antacid. Rationale: High-dose
non-selective NSAIDs like ibuprofen carry a high risk of
GI bleeding in an elderly patient with an ulcer history,
and simple antacids do not provide sufficient mucosal
protection.
• B) Indomethacin 50 mg twice daily combined with a low-
dose H2-receptor antagonist like famotidine. Rationale:
, Indomethacin has a very high rate of GI and CNS
toxicities in older adults and should be avoided; low-dose
H2 blockers do not fully protect against NSAID-induced
ulcers.
• C) Correct Answer: Celecoxib (a selective COX-2
inhibitor) combined with a proton pump inhibitor
(PPI) like omeprazole, or selecting non-NSAID
modalities like topical diclofenac. Rationale:
Celecoxib selectively inhibits COX-2, minimizing the
structural destruction of GI-protective prostaglandins
mediated by COX-1. In a high-risk patient (elderly with a
prior ulcer), pairing a COX-2 inhibitor with a PPI
provides the highest degree of upper GI protection if
systemic NSAID therapy is absolutely necessary. Topical
NSAIDs are even safer due to minimal systemic
absorption.
• D) Naproxen 500 mg twice daily, as it selectively protects
the gastric mucosal barrier while suppressing joint
inflammation lines. Rationale: Naproxen is a non-
selective NSAID that blocks both COX-1 and COX-2; it is
not gastric-protective.
4. A 28-year-old female patient who is at 8 weeks' gestation
requires treatment for severe chronic hypertension. Which
antihypertensive medication is considered safe for use
during pregnancy, and which is strictly contraindicated
due to structural teratogenic risks?
• A) Lisinopril is safe because it preserves renal perfusion;
Methyldopa is contraindicated due to maternal depression
risks. Rationale: ACE inhibitors like lisinopril are
strictly contraindicated in pregnancy due to severe fetal
renal anomalies.
